Formosyn A
Latest Information Update: 24 Sep 2007
At a glance
- Originator Oxford GlycoSciences; Tanabe Seiyaku
- Class Anti-inflammatories
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 02 Dec 1998 No Development Reported for Inflammation (Unknown route)
- 14 Nov 1995 Preclinical development for Inflammation (Unknown route)